A Phase 3 interventional study of 10% Metronidazole Ointment in Crohn's Disease, sponsored by S.L.A. Pharma AG. Completed at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-12-13.
Sponsored by S.L.A. Pharma AG · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 217 studies in Crohn Disease with a site in United Kingdom — 47 open to participants now, 66 under way, 26 of them phase 3. Crohn Disease · United Kingdom.
Among the 217 studies in Crohn Disease with a site in United Kingdom, this one is the 120th largest by enrollment of the 171 interventional ones that give a count, is one of 2 that started in 2005, is one of 71 in phase 3, and was the 19th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →47 of the 217 studies in Crohn Disease with a site in United Kingdom are open now. Recruiting first, the newest first:
Agomab Spain S.L.U. · Sites in United Kingdom, United States, Serbia
Ages 18+
Agomab Spain S.L.U. · Sites in United Kingdom
Ages 30–65 · Men only · Healthy volunteers
Hoffmann-La Roche · Sites in United Kingdom, United States, Australia and 5 more countries
Ages 2–17
Takeda · Sites in United Kingdom
Ages 18–75
University of Nottingham · Sites in United Kingdom
Ages 16+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
217 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 49 · Phase 3 75 · Phase 4 9
First in 2000; this study’s year is marked. 2 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 74 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 168 across the 171 interventional studies, 245 across the 46 observational. Of the 135 that completed or were terminated, 75 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
137 of 217 have an industry lead sponsor. The 10 most frequent:
S.L.A. Pharma AG is the lead sponsor of 11 studies on the registry; none are open to participants now.
S.L.A. Pharma AG has 1 study filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
14 of the studies in Crohn Disease with a site in United Kingdom that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06063967Phase 3AbbVieA Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. | 2027-03 |
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
| NCT03345823Phase 3AbbVieA Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | 2027-09 |
| NCT04779320Phase 3TakedaA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) | 2027-09-13 |
Add all 14 to your calendar (.ics) → With an account.
Among the 217 studies in Crohn Disease with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare changes in Perianal Crohn's Disease following use of locally applied 10% metronidazole ointment and a placebo.
Anorectal Crohn's disease is one of the most problematic and debilitating conditions encountered in colorectal practise. The condition is usually chronic, debilitating, and frequently refractory to current medications. Failure to respond to medical therapy may ultimately result in proctocolectomy and ileostomy, even in the absence of more proximal colonic disease. Isolated anorectal Crohn's disease is reported in 3 to 5% of Crohn's patients. In Crohn's patients as a whole, anorectal involvement is reported in up to one third to one half of patients, in addition to either colonic or enteric Crohn's disease. In spite of the previously reported painless nature of anorectal Crohn's disease, it is the author's experience that the condition can be inordinately painful due to deeply eroding fissures, oedematous skin tags, and painful induration of the perianal region.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metronidazole 10% ointment
Drug: 10% Metronidazole Ointment
Placebo ointment
Drug: 10% Metronidazole Ointment
Metronidazole 10% ointment applied perianally three times daily for four weeks. Placebo ointment applied perianally three times daily for four weeks
To evaluate the effect of 10% metronidazole ointment, applied topically three times a day, in and around the anus, on the change in perianal Crohn's disease activity.
Perianal Crohn's Disease Activity Index
Time frame: Four weeks
To evaluate and compare the relief of perianal pain and discomfort associated with Crohn's disease, against placebo.
Perianal Crohn's Disease Activity Index plus Visual Analogue Scale for perianal pain
Time frame: 4 weeks
To evaluate and compare Patient Global Impression of Improvement
Patient Global Impression of Improvement (numerical scale)
Time frame: 4 weeks
To compare visual improvement (using photographic documentation assessed by a blinded independent observer)
Photographic record
Time frame: 4 weeks
To compare Quality of Life assessments
Short Form 12 Questionnaire
Time frame: 4 weeks
To evaluate and compare the number of analgesics required prior to treatment and to that required by the treatment and placebo group
Usage of analgesics during the treatment period
Time frame: 4 weeks
To evaluate and compare fistula healing
Visual assessment of fistula healing
Time frame: 4 weeks
The record gives a start of May 2005, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metronidazole
S.L.A. Pharma AG